Teratogenic and clastogenic effects of BUdR in mice.
Pregnant mice (C57B1/6JFfm) were treated with BUdR on day 9 of gestation. For doses ranging from 300 to 1,200 mg/kg b.w. of BUdR the teratogenic effect in near-term fetuses was analyzed. The findings confirm the phase and dose dependency of the induced malformations found by other authors. They also demonstrate, however, a BUdR-specific induction of special malformations. For a dose of 1,200 mg/kg of BUdR the effect on mitotic rates and the induction of chromosomal aberrations were investigated. Mitotic rates were counted in single organs as well as in total homogenized embryos. The methods are equally useful. The embryos were analyzed 3, 6, 12, and 24 hours after BUdR treatment either after homogenization or in serial sections. Decrease of mitotic rates has been found to be most remarkable at 3 and 12 hours after treatment. At 24 hours only the neural tissue showed a slight decrease of the mitotic rate. Chromosomal aberrations are induced at all times, but the highest rates are seen at 3 and 12 hours after treatment. The aberrations are of the chromatid type.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D001842:Bone and Bones / Q000002:abnormalities; D001973:Bromodeoxyuridine / Q000009:adverse effects*; D002869:Chromosome Aberrations; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D008938:Mitosis / Q000187:drug effects; D009153:Mutagens; D011247:Pregnancy
D009153:Mutagens; D001973:Bromodeoxyuridine